Skip to main content

Advertisement

SpringerLink
Log in

Multiple sclerosis: Symptomatic treatment

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Therapy for multiple sclerosis (MS) that prevents exacerbation of the disease and slows the progression of disability has not diminished the importance of treating symptoms. Because the new agents are not curative and rarely reverse existing deficits, many patients under treatment have or will have persistent symptoms. Many neurologic symptoms are seen in patients with MS, but it is important to recognize that some nonneurologic symptoms, such as pain, fatigue, and mood disturbance, are common and may cause significant disability. The first and most important step in the management of symptoms is to discuss the symptoms with the patient on an ongoing basis. The second step is to recognize treatable symptoms and to apply the appropriate strategies for management. There have been promising results with experimental agents, primarily potassium channel blockers, that may improve function in demyelinated fiber pathways and that offer the possibility of treatment for a range of symptoms. At present, the management of symptoms varies, depending on the symptom, and it involves the coordinated application of a range of treatment approaches including medication, lifestyle changes, rehabilitation, and, in some cases, surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Trelles L, Trelles J, Castro C, et al.: Successful treatment of two cases of intention tremor with clonazepam [letter]. Ann Neurol 1984, 16:621.

    Article  PubMed  CAS  Google Scholar 

  2. Henkin Y, Herishanu Y: Primidone as a treatment for cerebellar tremor in multiple sclerosis: two case reports. Isr J Med Sci 1989, 25:720–721.

    PubMed  CAS  Google Scholar 

  3. Bozek C, Kastrukoff L, Wright J, et al.: A controlled trial of isoniazid therapy for action tremor in multiple sclerosis. J Neurol 1987, 234:36–39.

    Article  PubMed  CAS  Google Scholar 

  4. Goldman M, Kelly P: Symptomatic and functional outcome of stereotactic ventralis lateralis thalamotomy for intention tremor. J Neurosurg 1992, 77:223–229.

    PubMed  CAS  Google Scholar 

  5. Hewer R, Cooper R, Morgan M: An investigation into the value of treating intention tremor by weighting the affected limb. Brain 1972, 95:579–590.

    Article  PubMed  CAS  Google Scholar 

  6. Aisen M, Arnold A, Baiges I, et al.: The effect of mechanical damping loads on disabling action tremor. Neurology 1993, 43:1346–1350.

    PubMed  CAS  Google Scholar 

  7. Rice G, Lesaux J, Vanervoort P, et al.: Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor. J Neurol Neurosurg Psychiatry 1997, 62:282–284. This small, double-blind, placebo-controlled, crossoverdesign trial examined the effect of intravenously administered ondansetron in 20 patients with multiple sclerosis. Several measures of intention tremor were examined, and a statistically significant benefit was demonstrated.

    PubMed  CAS  Google Scholar 

  8. Geny C, Nguyen J, Pllin B, et al.: Improvement of severe postural cerebellar tremor in multiple sclerosis by chronic thalamic stimulation. Mov Disord 1996, 11:489–494.

    Article  PubMed  CAS  Google Scholar 

  9. Valiquette G, Herbert J, Maede-D’Alisera P: Desmopressin in the management of nocturia in patients with multiple sclerosis. Arch Neurol 1996, 53:1270–1275. Seventeen patients with multiple sclerosis who had nocturia were enrolled in a randomized, double-blind, placebo-controlled, crossover-design trial to assess the efficacy of desmopressin administered by nasal insufflation at bedtime. A statistically significant benefit was demonstrated.

    PubMed  CAS  Google Scholar 

  10. Gajewski J, Awad S: Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol 1986, 135:966–968.

    PubMed  CAS  Google Scholar 

  11. Blaivis J, Labib K, Michalik S, Zayed A: Cystometric response to propantheline in detrusor hyperreflexia: therapeutic considerations. J Urol 1980, 124:259–262.

    Google Scholar 

  12. Krupp L, Coyle P, Doscher C, et al.: Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline and placebo. Neurology 1995, 145:1956–1961. This randomized, double-blind, crossover-design, three-armed trial compared the efficacy of amantadine, pemoline, and placebo in treating fatigue in 93 patients with multiple sclerosis using a new fatigue rating scale. The study demonstrated that amantadine was superior to the other treatments and that pemoline, in the doses administered, was no better than placebo. In addition, it was shown that efficacy was not caused by a change in depression, sleep pattern, or overall disability.

    Google Scholar 

  13. van Diemen HA, Polman CH, van Dongen TM, et al.: The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized placebo-controlled, double-blind, crossover study. Ann Neurol 1992, 32:123–130.

    Article  PubMed  Google Scholar 

  14. Petajan J, Gappmaier E, White A, et al.: Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 1996, 39:432–441. This is a landmark study that demonstrated the clear benefit of exercise for patients with multiple sclerosis. Fifty-four patients were enrolled randomly either to an exercise or to a nonexercise group. The exercise group participated in 40 minutes of aerobic training 3 times a week for 15 weeks. Improvements were seen in fitness and quality of life.

    Article  PubMed  CAS  Google Scholar 

  15. Bever CT, Young D, Anderson PM, et al.: The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 1994, 44:1054–1059.

    PubMed  Google Scholar 

  16. Bever C, Andersen P, Leslie J, et al.: Treatment with oral 3,4-diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 1996, 47:1457–1462.

    PubMed  CAS  Google Scholar 

  17. Espir M, Millac P: Treatment of paroxysmal disorders in multiple sclerosis with carbamazepine. J Neurol Neurosurg Psychiatry 1970, 33:528–531.

    PubMed  CAS  Google Scholar 

  18. Solaro C, Lunardi G, Capello E, et al.: An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology 1998, 51:609–611.

    PubMed  CAS  Google Scholar 

  19. Kirkeby H, Poulsen E, Petersen T, Dorup J: Erectile dysfunction in multiple sclerosis. Neurology 1988, 38:1366–1371.

    PubMed  CAS  Google Scholar 

  20. Massey E, Pleet D: Penile prosthesis for impotence in multiple sclerosis. Ann Neurol 1979, 6:451–453.

    Article  PubMed  CAS  Google Scholar 

  21. Goldstein I, Lue T, Padma-Nathan H, et al.: Oral sildenafil in the treatment of erectile dysfunction: Sildenafil Study Group. N Engl J Med 1998, 338:1397–1404. This article reports the results of a large multicenter, randomized, placebo-controlled trial that demonstrated the efficacy of oral sildenafil.

    Article  PubMed  CAS  Google Scholar 

  22. Borg-Stein J, Pine Z, Miller J, Brin M: Botulinum toxin for the treatment of spasticity in multiple sclerosis: new observations. Am J Phys Med Rehabil 1993, 72:364–368.

    Article  PubMed  CAS  Google Scholar 

  23. Feldman R, Kelly-Hayes M, Conomy J, Foley J: Baclofen for spasticity in multiple sclerosis: double-blind crossover and three year study. Neurology 1978, 28:1094–1098.

    PubMed  CAS  Google Scholar 

  24. Coffe Y, Cahill D, Steers W, et al.: Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg 1993, 78:226–232.

    Article  Google Scholar 

  25. United Kingdom Tizanidine Trial Group: A doubleblind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology 1994, 44:S70-S78.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of Maryland, The Maryland Center for Multiple Sclerosis and Neurology and Research Services, VAMHCS, 22 South Greene St., 21201, Baltimore, MD, USA

    Christopher T. Bever Jr MD

Authors
  1. Christopher T. Bever Jr MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bever, C.T. Multiple sclerosis: Symptomatic treatment. Curr Treat Options Neurol 1, 221–237 (1999). https://doi.org/10.1007/s11940-999-0005-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-999-0005-9

Keywords

Search

Navigation